Ig20Gly Tolerability and Infusion Characteristics in Pediatric and Advanced Age Patients With Primary Immunodeficiency DiseasesJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22019-02-010OAAI
Onboarding Experience of Patients With Primary Immunodeficiency Diseases Who Switched to Subcutaneous Human Immune Globulin 20% (Ig20Gly) From Intravenous or Subcutaneous Immune Globulin 10%JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22018-02-010OAAI
Response to the Letter to the Editor Regarding Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical TrialsJOURNAL OF CLINICAL IMMUNOLOGYIF5.72017-09-050OAAI
Evaluation of the Safety, Tolerability, and Pharmacokinetics of GammaplexA® 10% Versus GammaplexA® 5% in Subjects with Primary ImmunodeficiencyJOURNAL OF CLINICAL IMMUNOLOGYIF5.72017-03-1813OAAI
Review of the Onboarding Experience of a New 20% Human Immune Globulin for Subcutaneous Administration (SCIG 20%): Correlation of Infusion Parameters and Adverse Events (AEs)JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22017-02-010OAAI
A New Liquid 10% Intravenous Immunoglobulin (IVIG) Administered with 15-Minute Titration Periods Allows Shorter Infusion Durations and Tolerability Similar to a 5% FormulationJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22017-02-010PREAI
A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North AmericaJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22017-02-010PREAI
Analyses of a Subset of Patients with Primary Immunodeficiency Diseases (PIDD) Who Switched Modes of Administration of Immunoglobulin (Ig) Therapy during Three Consecutive StudiesJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22017-02-010OAAI
Modified Oral Rapid Drug Desensitization (ORDD) to Ibrutinib in a Patient with Stage IV Mantle Cell Lymphoma and Early Onset Grade 1 Hypersensitivity ReactionJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22017-02-012PREAI
Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North AmericaJOURNAL OF CLINICAL IMMUNOLOGYIF5.72016-08-3151OAAI
Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency DiseaseJOURNAL OF CLINICAL IMMUNOLOGYIF5.72016-06-2026OAAI
Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary ImmunodeficiencyJOURNAL OF CLINICAL IMMUNOLOGYIF5.72016-05-2535OAAI
Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (IGHy) in Patients with Primary Immunodeficiency Disease (PIDD): Infections over TimeJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22016-02-010OAAI
Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North AmericaJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22016-02-010OAAI
Local Adverse Reaction Rates Decreased over Time during Treatment with Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients with Primary Immunodeficiency Disorders in the IGHy Phase 3 StudiesJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22016-02-011OAAI
Patients with Rheumatologic Disorders May Develop Pain with Immunoglobulin Replacement, Requiring the Use of Daily Subcutaneous TherapyJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22015-02-010OAAI
Pharmacokinetics of RI-002, an Investigational Igiv PreparationJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22015-02-010OAAI
Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)-Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI)JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22015-02-012PREAI
Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency diseaseCLINICAL AND EXPERIMENTAL IMMUNOLOGYIF3.82015-01-02133OAAI
Long-Term Tolerability and Safety Of Facilitated-Subcutaneous Infusion Of Human Immune Globulin G (IgG), 10%, and Recombinant Human Hyaluronidase (rHuPH20) (IGHy): A Phase 3 Extension Study In Patients With Primary Immunodeficiencies (PIs)JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYIF11.22014-02-011PRE